top of page
Final_Open call Isidore.jpg

EVI-led

TRANSVAC2

is now also offering

services as part of

ISIDORe, Integrated

Services for Infectious Disease Outbreak Research, to support scientists and their research on epidemic- and pandemic-prone pathogens. 

OPEN CALL

Are you a researcher developing a new COVID-19 or Monkeypox vaccine candidate?

Apply now >>

This is a great place to tell your story and give people more insight into who you are, what you do, and why it’s all about you.

Neglected 

diseases

mainly affect low income population

 have the potential

  to cause global

 outbreaks and

epidemics

THE CHALLENGE

Emerging

    diseases 

Neglected and emerging infectious diseases disproportionately affect the lives of people and children living in low- and middle-income countries, causing sickness, disability and death to millions, and also represent a significant and growing threat worldwide.

Global
village

Vaccines are among the most successful and cost-effective public health tools for preventing diseases and death. Each year, more than three million lives are saved and millions more are protected from disease and disability, thanks to vaccination.

Vaccines, the way forward
OUR WORK

Diseases 

EVI has a Vaccine Projects' Portfolio that addresses critical R&D challenges and opportunities in five disease areas:

Malaria is caused by Plasmodium 

parasites and spread to people through mosquitoes. 90% of all cases occur in the WHO Africa Region.

Leishmaniasis is caused by a protozoan parasite and transmitted to humans by sandflies. Over 1 billion people are at risk from leishmaniasis.

IMG_5584_edited.jpg

Nipah virus can be transmitted from animals (pigs, bats), contaminated food or directly between people. The case fatality rate ranges from 40% to 100%.

Zika is an emerging mosquito-borne virus. Zika virus infection during pregnancy can cause infants to be born with congenital Zika syndrome.

Image by National Cancer Institute

Cross-cutting Activities

EVI is committed to supporting vaccine development beyond individual vaccine candidates. EVI engages in initiatives aimed at creating harmonisation between stakeholders, promote networking and support access to vaccine infrastructures as well as capacity strengthening activities at the European and global level. 

EVI is committed to establishing a European vaccine R&D infrastructure to accelerate the development of prophylactic and therapeutic vaccines for human and animal health.

EVI is supporting the development and validation of non-animal approaches for testing quality of human and veterinary vaccines.

Cross-cutting activities

Diarrhoeal diseases are the 2nd leading cause of death in children under five. Shigella and Enterotoxigenic E. coli are major causes of diarrhoea worldwide.

EVI seeks to create sustainable health networking, knowledge hubs and  facilitate 

cooperation of mutual benefit in health research and innovation.

EVI is working across Europe to harmonise key vaccine assays, through standardised lab procedures, preparations, and reagents, and by promoting their uptake and use.

OUR ACHIEVEMENTS

EVI at a glance

Since its inception in 1998, EVI has succeeded in establishing and maintaining an ‘enabling environment’ that accelerates vaccine development and has developed synergies and collaborations with multiple partners, including other Product Development Partnerships (PDPs), academia, research institutions, pharma and biotechnology companies, policy makers regulatory agencies and donors.

 

In 2020, EVI supported:

10 vaccine R&D projects

5 disease areas

6 vaccine candidates

in clinical development

​

bottom of page